78 Percent More Capital for German Biotech
Financing for companies in Germany rose markedly in 2024, with interest particularly strong in cancer treatments.
Your company is already operating in Germany and you would now like to export worldwide?
Financing for companies in Germany rose markedly in 2024, with interest particularly strong in cancer treatments.
Join the DACH Invest MedTech event and get the latest updates from the DACH countries.
This forum explores business opportunities in the largest and most important healthtech regions in Europe.
The pharmaceuticals and chemicals giant is investing a hefty nine-figure in a state-of-the-art facility in its home city of Darmstadt.
Germany’s healthcare sector enjoyed a successful year with a resurgent biotech sector generating a quarter of new capital. New therapies are being developed for a range of autoimmune diseases and telemedicine service are on the rise.
The injectable Mounjaro that will be mass produced by Eli Lilly and Company in Germany has been cleared for use in helping people shed pounds.
In 2023, there was a notable resurgence in the financing available to Germany's biotechnology sector.
Germany is undertaking a “digital revolution” in healthcare and now has a strategy to make life easier for pharmaceutical companies.
Innovative start-ups are booming in Germany's attractive life sciences sector.
Japanese pharmaceuticals giant Takeda has put hundreds of millions of euros in recent years into its location in the southwestern German town of Singen to produce its anti-dengue-fever vaccine “Qdenga.”
The mood in German pharmaceuticals is bright, with companies looking to increase investment.